Fluidigm Sees 2013 as 'Watershed Year' for Single-Cell Genomics, as C1 Sales Drive Q1 Revenues | GenomeWeb

This article was originally posted on May 3.

Fluidigm continues to benefit from its efforts to serve single-cell genomics researchers.

The South San Francisco, Calif.-based biochip company last week reported a 33-percent spike in first quarter revenues, driven by sales of its C1 Single-Cell AutoPrep System, as well as increased demand for its integrated fluidic circuit chips from its agricultural and clinical laboratory clients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.